We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+10.77%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.78B
AUM Growth
+$316M
Cap. Flow
+$35.3M
Cap. Flow %
0.93%
Top 10 Hldgs %
64.41%
Holding
33
New
1
Increased
14
Reduced
7
Closed
1

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$33.6M
2
ARGX icon
argenx
ARGX
+$25.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.1M
4
NKTR icon
Nektar Therapeutics
NKTR
+$18.2M
5
TSRO
TESARO, Inc.
TSRO
+$17.8M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$31.7M
2
CELG
Celgene Corp
CELG
+$30M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$26.6M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$18.1M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$15.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
26
DELISTED
Alder Biopharmaceuticals
ALDR
$37.7M 1%
2,266,008
– –
MYOK
27
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$33.3M 0.88%
510,000
+30,000
+6% +$1.76M
GTHX
28
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$22.2M 0.59%
425,318
+72,711
+21% +$3.96M
NVAX icon
29
Novavax
NVAX
$1.21B
$15.7M 0.41%
416,500
– –
CDTX
30
DELISTED
Cidara Therapeutics
CDTX
$10.1M 0.27%
114,764
– –
SRRK icon
31
Scholar Rock
SRRK
$5.88B
$4.89M 0.13%
+189,957
New +$3.49M
ACHN
32
DELISTED
Achillion Pharmaceuticals
ACHN
$4.71M 0.12%
1,279,340
– –
FPRX
33
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-977,500
Closed -$15.5M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2018 Portfolio in Review

As of Q3 2018, BB Biotech held 33 positions worth $3.78B, up 9.1% from $3.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

BB Biotech's Q3 2018 filing shows 1 new, 14 increased, 7 reduced and 1 closed positions. Its largest new stake was Scholar Rock: 189,957 shares worth $4.89M. The largest sale was Gilead Sciences, an estimated $31.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

  • BB Biotech's largest Q3 2018 buy was Scholar Rock: 189,957 shares worth $4.89M.
  • BB Biotech added most to Exelixis in Q3 2018, an estimated $33.6M increase.
  • BB Biotech's biggest Q3 2018 reduction was Gilead Sciences, cutting an estimated $31.7M.
  • BB Biotech fully exited Five Prime Therapeutics, Inc. in Q3 2018, selling an estimated $15.5M.
  • BB Biotech's ten largest holdings make up 64% of its $3.78B portfolio in Q3 2018.
  • BB Biotech opened 1 new position and closed 1 in Q3 2018.
  • BB Biotech's portfolio value rose 9.1% quarter-over-quarter to $3.78B.

Based on BB Biotech's 13F filing for Q3 2018, filed 9 Nov 2018.